Company intelligence / Profile preview

Think Therapeutics

Boulder, Colorado, United Statesthinktx.co ↗

Ownership: Private
Development stage: Other

Overview

No clinical results yet; the company is focused on preclinical discovery and development of small-molecule drugs targeting historically undruggable proteins using a proprietary synthetic biology platform. The company has raised significant seed funding to expand its drug discovery efforts and internal pipeline but has not advanced any candidates into clinical trials as of June 2025.

Therapeutic areas: ImmunologyMetabolic DisordersOncology
Modalities: Small moleculeBiologic (via synthetic biology platform)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly announced as of June 2025. Investors include venture capital firms specializing in deep tech/biotech.

Beyond the preview

Go deeper on Think Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Think Therapeutics.

Explore the full profile